Recent studies have reported that PTPRT mutations may be associated with the tumor mutation burden (TMB) and could provide clinically predictive implications for immune checkpoint inhibitor (ICI) therapies [8, 9]. The gene discussed is PTPRT; the disease is neoplasm.